Abstract: Slide Presentations |


Xiaoqin Zhou, MD*; Dongfang Wang, MD; Cherry Croft, PhD; Philip Freidenreich, PhD; Sanford R. Simon, PhD; Hsi-ming Lee, PhD; Joseph B. Zwischenberger, MD
Author and Funding Information

University of Kentucky, Lexington, KY


Chest. 2009;136(4_MeetingAbstracts):61S. doi:10.1378/chest.136.4_MeetingAbstracts.61S-h
Text Size: A A A
Published online


PURPOSE:  Acute respiratory distress syndrome (ARDS) is the major cause of death in patients with severe smoke/burn injury. Activated neutrophils which release metalloproteinases (MMPs) are thought to play a role in this lung injury. The new non-antimicrobial tetracycline, COL-3, is an inhibitor of MMPs. Our goal, therefore, was to evaluate the therapeutic efficacy of COL-3 in our smoke/burn/barotrauma sheep ARDS model.

METHODS:  Under general anesthesia, sheep underwent smoke inhalation (4X12 breaths) and a third-degree burn injury (40% total body surface area). Ventilator –induced barotrauma (PS 40 cm H2O) was initiated immediately after the smoke/burn injury. Low tidal volume ventilation was applied when ARDS criteria (PaO2/FiO2 <200) was met or at 24 hr post injury if criteria were not met. Sheep were assigned to Vehicle (n=5, 10% Solutol HS 15) or the COL-3 group (n = 5, 200mg/m2 body surface). Vehicle or COL-3 was administered intravenously one hour after smoke/burn injury. At 96 hr or at time of death, the experiment was terminated and necropsy was performed.

RESULTS:  ARDS criteria was met in 4/5 Vehicle and 4/5 COL-3 animals. The ARDS onset time was 13 ± 3.8 hr in Vehicle and 20.1 ± 3.6 hr in COL-3 group (P<0.05). Survival in the COL-3 sheep was significantly higher at 96 hours than in Vehicle (80%, 4/5 COL-3 vs 20%, 1/5 Vehicle). COL-3 animals also showed a longer survival compared with Vehicle (59 ± 26 hr vs 94 ± 4 hr, P<0.05). Lung wet-to-dry weight ratio was lower in COL-3 animals (5.840 ± 1.082 vs 7.428 ± 0.563). MMP-2 levels increased in Vehicle but not in COL-3 treated sheep. No significant toxicity was found in COL-3 treated compared to Vehicle animals.

CONCLUSION:  Administration of COL-3 shortly after severe smoke-burn exposure delayed ARDS development and improved 96 hr survival in our ovine ARDS model.

CLINICAL IMPLICATIONS:  Our findings show that COL-3 has a potential therapeutic benefit in the treatment of ARDS.

DISCLOSURE:  Xiaoqin Zhou, No Financial Disclosure Information; No Product/Research Disclosure Information

Wednesday, November 4, 2009

2:15 PM - 3:15 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543